Which of the following is NOT used to treat low titre FVIII inhibitors (<5 BU)?

Get ready for the CAMLPR Hematology Test. Use our quizzes, flashcards, and detailed explanations to enhance your understanding. Prepare confidently for your exam!

Multiple Choice

Which of the following is NOT used to treat low titre FVIII inhibitors (<5 BU)?

The main idea is that inhibitors to factor VIII change how we approach bleeding control: therapies must either bypass the need for FVIII or provide FVIII that the antibodies don’t neutralize. Desmopressin works by releasing stored FVIII (and von Willebrand factor) into the circulation, which can help in mild hemophilia A. However, when anti-FVIII antibodies are present—even at low levels—they quickly neutralize the newly released FVIII, making the rise in FVIII activity unreliable for achieving hemostasis. Because of this, desmopressin is not a dependable treatment option for bleeds in patients with low-titer FVIII inhibitors. In contrast, porcine FVIII is used because many human FVIII inhibitors do not recognize porcine FVIII in the same way, allowing a functional FVIII activity to be achieved. Intriguingly, options like IVIG are relevant in immune-mediated inhibitors—such as acquired hemophilia A—where immune modulation can reduce inhibitor activity. FIX concentrates, by themselves, do not supply FVIII and do not address the deficiency caused by FVIII inhibitors, so they are not used to treat FVIII inhibitors.

The main idea is that inhibitors to factor VIII change how we approach bleeding control: therapies must either bypass the need for FVIII or provide FVIII that the antibodies don’t neutralize. Desmopressin works by releasing stored FVIII (and von Willebrand factor) into the circulation, which can help in mild hemophilia A. However, when anti-FVIII antibodies are present—even at low levels—they quickly neutralize the newly released FVIII, making the rise in FVIII activity unreliable for achieving hemostasis. Because of this, desmopressin is not a dependable treatment option for bleeds in patients with low-titer FVIII inhibitors.

In contrast, porcine FVIII is used because many human FVIII inhibitors do not recognize porcine FVIII in the same way, allowing a functional FVIII activity to be achieved. Intriguingly, options like IVIG are relevant in immune-mediated inhibitors—such as acquired hemophilia A—where immune modulation can reduce inhibitor activity. FIX concentrates, by themselves, do not supply FVIII and do not address the deficiency caused by FVIII inhibitors, so they are not used to treat FVIII inhibitors.

More practice questions